Invivyd completes phase 3 trial enrollment
Share
- Invivyd completed enrollment in its Phase 3 LIBERTY trial evaluating a COVID-19 antibody.
- The company's share price traded down at $0.86 following the clinical milestone announcement.
- The trial supports the development of VYD2311 within the company's broader REVOLUTION prevention program.
Invivyd (NASDAQ:IVVD) completed enrollment in its Phase 3 LIBERTY trial to evaluate a potential COVID-19 prevention option.
The randomized study focuses on side effects and patient tolerability over a seven-day window.
The trial also assesses safety and immune responses when administering the drug alongside an mRNA vaccine.
The company stated that initial topline data are expected to be released in the third quarter of 2026.
The ongoing study represents a component of the broader REVOLUTION clinical development program.
Management indicated that these outcomes may be reported alongside results from the pivotal DECLARATION trial.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
